Rheumatoid
arthritis (RA) is the
most common autoimmune arthritis affecting more than 1.3 million U.S.
citizens (American College of Rheumatology). More surprising is to
know that around 75% of this affected population is women. Affecting
the joints at any age, rheumatoid arthritis needs to be addressed
early to avoid expensive joint replacement surgery. While it can
affect any joint, small joints in hand and feet tend to be affected
the most. Treatments available for rheumatoid arthritis aids to
relive symptoms and improve the joint function. A comprehensive
treatment for RA usually involves integration of patient education,
exercise, medications, and surgery (occasionally). The rheumatoid
arthritis treatment market can be analyzed based on the drug type, as
follows:
Biological drugs:
• Monoclonal antibodies
Non-Biologicals:
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Analgesics
• Disease-modifying anti-rheumatic drugs (DMARDs)
- IL-6 inhibitors
- TNF inhibitors
Download
PDF Brochure of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/166
NSAIDs and corticosteroid are also the first-line fast acting
therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac,
and diclofenac are the NSAIDs usually prescribed as first-line drugs
for RA. These drugs reduce inflammation, and pain. Corticosteroid
medications are given either orally or parenterally to reduce
inflammation and restore joint mobility and function. These class of
drugs are more potent than NSAIDs and therefore usually preferred a
first line therapy by prescribers. The global rheumatoid arthritis
treatment industry is expected to be driven considerably in near
future by DMARDs that form second line slow-acting therapeutic drugs.
Longer therapeutic regimen with these drugs increases cost of therapy
and also promote remission of joint destruction and deformity.
Methotrexate is the most commonly prescribed second line drug for RA
and hence, occupies major share in the respective segment of global
rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the
most potential FDA approved Janus kinase (JAK) inhibitor available in
the global market of rheumatoid arthritis treatment.
Key statistics pertaining to the global rheumatoid arthritis
treatment market:
Over time, there is damage to cartilage and mobility function of the
affected joint in rheumatoid arthritis patient.
• Affects nearly 1.3 million U.S. population
(RheumatoidArthritis.org)
• Most common in the age group of 30-60 years
• Global prevalence varies in the range of 0.3% to 1% (World Health
Organization)
• Average annual cost of treatment may go up to US $20,000
(RheumatoidArthritis.org)
• According to the Arthritis Foundation, people with RA loose more
workdays compared to those affected by any other medical condition
• According to a Harvard University study published in the Journal
of Global Health (2017), prevalence of rheumatoid arthritis in
Southeast Asian countries was 0.4%, 0.42 in western Pacific region,
and 0.37% in eastern Mediterranean countries
Global Key Players
Some of the major players in the global rheumatoid arthritis
treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie,
Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen,
Inc.,
Grab
Best Discount on This Research Report @
https://www.coherentmarketinsights.com/insight/request-discount/166
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment